Compare Upwork Inc (UPWK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Upwork Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Upwork Inc trades at $8.57 (market cap $1.07B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 119.2× Upwork Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Upwork Inc for 38 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| UPWK | VRTX | |
|---|---|---|
Market Cap | $1.07B | $127.55B |
Volume | 2,574,130 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $22.11 | $557.96 |
52-Week Low | $7.84 | $407.37 |
Typical Hold Time | 38 Days | 120 Days |
Enterprise Value | $833.01M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Upwork (UPWK) trades at $8.40, up 0.48% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 EPS of $0.41, beating expectations, but revenue growth has slowed, with 2025 revenue at $787.78 million. Valuation metrics appear attractive with a P/E of 10.77 and P/S of 1.45. Recent news highlights insider sales and a securities fraud investigation, while Bank of America acquired a significant stake.
The outlook is mixed: low valuation and strong profitability margins offer upside, but AI competition and recent insider selling pose risks. Analyst consensus is a Buy with a $9.64 price target, implying potential appreciation, though sentiment is cautious due to growth concerns and legal scrutiny.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
